Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92.

Article  PubMed  PubMed Central  Google Scholar 

Testori AAE, Chiellino S, van Akkooi ACJ. Adjuvant therapy for melanoma: past, current, and future developments. Cancers (Basel). 2020;12(7):1994. https://doi.org/10.3390/cancers12071994.

Article  CAS  PubMed  Google Scholar 

Eggermont AMM, Chiarion-Sileni V, Grob J, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.

Article  CAS  PubMed  Google Scholar 

Eggermont AMM, Chiarion-Sileni V, Grob J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.

Article  CAS  PubMed  Google Scholar 

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801.

Article  CAS  PubMed  Google Scholar 

Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson V, Dalle S, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. J Clin Oncol. 2020;38(Suppl_15):10000.

Article  Google Scholar 

Lewis K, Maio M, Demidov L, Mandala M, Ascierto PA, Herbert C, et al. LBA7_PR - BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence. Ann Oncol. 2017;28:v631–2.

Article  Google Scholar 

Testori AAE, Ribero S, Indini A, Mandalà M. Adjuvant treatment of melanoma: recent developments and future perspectives. Am J Clin Dermatol. 2019;20(6):817–27.

Article  PubMed  Google Scholar 

Coens C, Suciu S, Chiarion-Sileni V, Grob J, Dummer R, Wolchok JD, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017;18(3):393–403.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–23.

Article  CAS  PubMed  Google Scholar 

Nederlandse Melanoom Werkgroep: Landelijke richtlijn melanoom (National Melanoma Guideline (Dutch)). Integraal Kankercentrum Nederland (IKNL), the Netherlands Comprehensive Cancer Organisation; 2019. https://richtlijnendatabase.nl/gerelateerde_documenten/f/12160/Oncoline%20-%20Melanoom.pdf.

van den Eertwegh F: Adjuvante behandeling van het hoogrisicomelanoom. WIN-O Werkgroep Melanoom 2018. https://www.nvmo.org/wp-content/uploads/2018/11/E-pub-MO-nov-2018-Consensus-WIN-O-adjuvante-behandeling-hoogrisicomelanoom.pdf.

NVMO-commissie B: Adjuvant pembrolizumab bij stadium III melanoom. NVMO 2019. https://medischeoncologie.nl/uploads/magazines/oncologie/2023/10/articles/mo-10-2023-bom-adjuvant-pembrolizumab-bij-stadium-iii-melanoom.pdf.

Hanna TP, Nguyen P, Baetz T, Booth CM, Eisenhauer E. A population-based study of survival impact of new targeted and immune-based therapies for metastatic or unresectable melanoma. Clin Oncol. 2018;30(10):609–17.

Article  CAS  Google Scholar 

van Not OJ, van den Eertwegh AJM, Haanen JB, Blank CU, Aarts MJB, van Breeschoten J, et al. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021. eClinicalMedicine. 2024;69:102485.

Article  PubMed  PubMed Central  Google Scholar 

Lao CD, Khushalani NI, Angeles C, Petrella TM. Current state of adjuvant therapy for melanoma: less is more, or more is better? Am Soc Clin Oncol Educ Book. 2022;42:738–44.

Article  Google Scholar 

Kobeissi I, Tarhini AA. Systemic adjuvant therapy for high-risk cutaneous melanoma. Ther Adv Med Oncol. 2022;14:17588359221134088.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharon CE, Straker RJ, Gimotty PA, Chu EY, Mitchell TC, Miura JT, et al. Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: a population-based analysis. J Am Acad Dermatol. 2022;88(4):802–7.

Article  PubMed  PubMed Central  Google Scholar 

Wolff D. Collagen Diseases. In: Enna SJ, Bylund DB, editors. xPharm: The Comprehensive Pharmacology Reference. New York: Elsevier; 2007. p. 1–9.

Google Scholar 

Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong T, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial—ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186–97.

Article  CAS  Google Scholar 

Jochems A, Bastiaannet E, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, et al. Outcomes for systemic therapy in older patients with metastatic melanoma: results from the Dutch Melanoma Treatment Registry. J Geriatr Oncol. 2021;12(7):1031–8.

Article  CAS  PubMed  Google Scholar 

Iacono D, Vitale MG, Basile D, Pelizzari G, Cinausero M, Poletto E, et al. Immunotherapy for older patients with melanoma: from darkness to light? Pigment Cell Melanoma Res. 2021;34(3):550–63.

Article  CAS  PubMed  Google Scholar 

Fleming NH, Tian J, de Miera EVS, Gold H, Darvishian F, Pavlick AC, et al. Impact of age on the management of primary melanoma patients. Oncology. 2013;85(3):173–81.

Article  PubMed  Google Scholar 

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016;532(7598):250–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fane ME, Ecker BL, Kaur A, Marino GE, Alicea GM, Douglass SM, et al. sFRP2 supersedes VEGF as an age-related driver of angiogenesis in melanoma, affecting response to anti-VEGF therapy in older patients. Clin Cancer Res. 2020;26(21):5709–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain V, Hwang W, Venigalla S, Nead KT, Lukens JN, Mitchell TC, et al. Association of age with efficacy of immunotherapy in metastatic melanoma. Oncologist. 2020;25(2):e381–5.

Article  CAS  PubMed  Google Scholar 

West H, Jin JO. Performance status in patients with cancer. JAMA Oncol. 2015;1(7):998.

Article  PubMed  Google Scholar 

Boland P, Pavlick AC, Weber J, Sandigursky S. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. J Immunother Cancer. 2020;8(1): e000356. https://doi.org/10.1136/jitc-000356.

Article  PubMed  PubMed Central  Google Scholar 

Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer. 2017;75:24–32.

Article  CAS  PubMed  Google Scholar 

Lessomo FYN, Mandizadza OO, Mukuka C, Wang Z. A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. Eur J Med Res. 2023;28(1):495.

Article  PubMed  PubMed Central  Google Scholar 

El Sharouni M, Rawson RV, Sigurdsson V, Witkamp AJ, van Gils CH, Scolyer RA, et al. The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15 mm in thickness). J Am Acad Dermatol. 2022;87(2):298–305.

Article  PubMed  Google Scholar 

Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643–54.

Article